These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8901669)

  • 1. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene.
    Séguret-Macé S; Latta-Mahieu M; Castro G; Luc G; Fruchart JC; Rubin E; Denèfle P; Duverger N
    Circulation; 1996 Nov; 94(9):2177-84. PubMed ID: 8901669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism.
    Francone OL; Gong EL; Ng DS; Fielding CJ; Rubin EM
    J Clin Invest; 1995 Sep; 96(3):1440-8. PubMed ID: 7657816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice.
    Holvoet P; De Geest B; Van Linthout S; Lox M; Danloy S; Raes K; Collen D
    Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):459-66. PubMed ID: 10669644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits.
    Hoeg JM; Vaisman BL; Demosky SJ; Meyn SM; Talley GD; Hoyt RF; Feldman S; Bérard AM; Sakai N; Wood D; Brousseau ME; Marcovina S; Brewer HB; Santamarina-Fojo S
    J Biol Chem; 1996 Feb; 271(8):4396-402. PubMed ID: 8626790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.
    Hoeg JM; Santamarina-Fojo S; Bérard AM; Cornhill JF; Herderick EE; Feldman SH; Haudenschild CC; Vaisman BL; Hoyt RF; Demosky SJ; Kauffman RD; Hazel CM; Marcovina SM; Brewer HB
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11448-53. PubMed ID: 8876155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractional efflux and net change in cellular cholesterol content mediated by sera from mice expressing both human apolipoprotein AI and human lecithin:cholesterol acyltransferase genes.
    Fournier N; Atger V; Paul JP; de la Llera Moya M; Rothblat G; Moatti N
    Atherosclerosis; 1999 Dec; 147(2):227-35. PubMed ID: 10559507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels.
    Miettinen HE; Gylling H; Tenhunen J; Virtamo J; Jauhiainen M; Huttunen JK; Kantola I; Miettinen TA; Kontula K
    Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):591-8. PubMed ID: 9555865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice.
    Dugi KA; Vaisman BL; Sakai N; Knapper CL; Meyn SM; Brewer HB; Santamarina-Fojo S
    J Lipid Res; 1997 Sep; 38(9):1822-32. PubMed ID: 9323591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile.
    Mehlum A; Staels B; Duverger N; Tailleux A; Castro G; Fievet C; Luc G; Fruchart JC; Olivecrona G; Skretting G
    Eur J Biochem; 1995 Jun; 230(2):567-75. PubMed ID: 7607230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice.
    Vaisman BL; Klein HG; Rouis M; Bérard AM; Kindt MR; Talley GD; Meyn SM; Hoyt RF; Marcovina SM; Albers JJ
    J Biol Chem; 1995 May; 270(20):12269-75. PubMed ID: 7744879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol.
    Kopfler WP; Willard M; Betz T; Willard JE; Gerard RD; Meidell RS
    Circulation; 1994 Sep; 90(3):1319-27. PubMed ID: 8087941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lecithin/cholesterol acyltransferase modulates diet-induced hepatic deposition of triglycerides in mice.
    Karavia EA; Papachristou DJ; Kotsikogianni I; Triantafyllidou IE; Kypreos KE
    J Nutr Biochem; 2013 Mar; 24(3):567-77. PubMed ID: 22819565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperalphalipoproteinemia in human lecithin cholesterol acyltransferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner.
    Brousseau ME; Santamarina-Fojo S; Zech LA; Bérard AM; Vaisman BL; Meyn SM; Powell D; Brewer HB; Hoeg JM
    J Clin Invest; 1996 Apr; 97(8):1844-51. PubMed ID: 8621767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions.
    Van Craeyveld E; Lievens J; Jacobs F; Feng Y; Snoeys J; De Geest B
    Gene Ther; 2009 Jun; 16(6):757-65. PubMed ID: 19242527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.
    Castro G; Nihoul LP; Dengremont C; de Geitère C; Delfly B; Tailleux A; Fievet C; Duverger N; Denèfle P; Fruchart JC; Rubin EM
    Biochemistry; 1997 Feb; 36(8):2243-9. PubMed ID: 9047326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical studies in a patient with a Tangier syndrome.
    Yao JK; Herbert PN; Fredrickson DS; Ellefson RD; Heinen RJ; Forte T; Dyck PJ
    J Neuropathol Exp Neurol; 1978; 37(2):138-54. PubMed ID: 632844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and characterization of polycistronic retrovirus vectors for sustained and high-level co-expression of apolipoprotein A-I and lecithin-cholesterol acyltransferase.
    Fan L; Owen JS; Dickson G
    Atherosclerosis; 1999 Nov; 147(1):139-45. PubMed ID: 10525135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochemistry; 2007 Sep; 46(37):10713-21. PubMed ID: 17711302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of a compound heterozygote: LCAT (Arg147 --> Trp) and LCAT (Tyr171 --> Stop).
    Guerin M; Dachet C; Goulinet S; Chevet D; Dolphin PJ; Chapman MJ; Rouis M
    Atherosclerosis; 1997 May; 131(1):85-95. PubMed ID: 9180249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.